Extended Data Fig. 5: GR-KO MCF7 xenografts generation and response to dexamethasone treatment, in vivo.
From: Fasting boosts breast cancer therapy efficacy via glucocorticoid activation
a. Western blot for GR in NT (non-targeting) and GR-KO MCF7 cells; Actin was used as loading control. Three biological replicates were performed (n = 3). For gel source data, see Supplementary Fig. 1. b. Immunofluorescence for DAPI and GR in NT and GR-KO MCF7 cells. Two biological replicates were performed (n = 2). c. Xenograft MCF7 GR-KO tumour volume in six/eight-week-old female athymic nude mice treated with vehicle or Dexa. Data are shown as mean ± SEM. Control n = 6, Dexa n = 5. n, number of tumours per treatment group. d. Representative IHC images for GR in MCF7 GR-KO and NT xenografts treated with vehicle or Dexa. GR-KO control n = 5, GR-KO dexa n = 4, NT n = 3. n, number of tumours analysed. e. Volcano plot of the differentially expressed transcripts between vehicle and Dexa treated MCF7 GR-KO xenografts. Differential gene expression was determined by two-sided Wald test. f. Enrichment plot of a pan-cancer GR-activity signature for the depicted conditions. NES is calculated by weighted Kolmogorov-Smirnov test and P-value determined by permutation-based testing with multiple Benjamini-Hochberg (BH) hypothesis correction.
